세계의 생체흡수성 폴리머 시장 : 유형별, 용도별, 지역별 - 예측(-2029년)

In terms of value, the bioresorbable polymers market is estimated to grow from USD 500.0 million in 2024 to USD 867.2 million by 2029, at a CAGR of 11.6%. Favorable regulations and policies by the government towards healthcare industry are positively influencing the bioresorbable polymers market. Various countries have created regulations that encourage manufacturers to increase biocompatibility & biodegradability of medical devices like orthopedic devices. These changes promote the creation of bioresorbable polymers. New technologies for the surgical implants are driving the demand for bioresorbable polymers. This further encourages businesses to invest in the bioresorbable polymers market.

"PCL type segment is projected to be the third-fastest growing segment of bioresorbable polymers market, during the forecast period"

PCL type segment is estimated to be the third-fastest growing segment of bioresorbable polymers market, during the forecast period. This demand is primarily due to its demand in drug delivery systems. The properties of biocompatibility and flexibility make PCL flexible and capable for use in any drug delivery format, such as injectable microparticles, implantable devices, and capsules. Compatibility with other bioresorbable polymers brings it as the first choice for customized formulations in advanced therapeutic systems.

"Drug delivery was the second largest end-use industry of bioresorbable polymers market, in terms of value, in 2023."

Drug delivery segment stands as the second-largest application in the bioresorbable polymers market. The demand is fueled by the need of controlled, targeted, and sustained-release drug systems, resulting in improved patient outcomes. Bioresorbable polymers are also widely employed in the preparation of implantable drug matrices and capsules to provide a slow and controlled release of therapeutic agents over time. This avoids the need for re-dose, thus significantly reducing discomfort to the patient. Their biocompatibility ensures that these polymers degrade safely within the body, well in line with the increasing trend by the medical industry towards innovative, patient-centered care solutions. With the desire for advanced drug delivery systems all over the world on the rise, bioresorbable polymers are among the most important choices when making efficient and effective therapeutic solutions.

"Europe was the second largest region in the bioresorbable polymers market, in terms of value."

Europe was the second-largest region in the bioresorbable polymers market, in terms of value, in 2023. The bioresorbable polymers market in the region is comparatively mature, growing slower than the developing markets in the Asia-Pacific region and South America. The demand of bioresorbable polymers in the European region is primarily due to the increasing prevalence of chronic diseases such as cancers, cardiovascular diseases, orthopedic disorders, and neurological conditions. Bariatric, trauma, orthopedic, and cardiovascular surgical procedures are also on the rise in Europe. The region has developed a strong health care infrastructure and increased the level of advanced medical research further, which has clearly enhanced this market for bioresorbable polymers offered as sustainable and biocompatible solutions for implants and drug delivery systems. Additionally, the support by regulatory towards biodegradable material-based medical devices helps to spread across the European market.

• By Company Type: Tier 1 - 55%, Tier 2 - 25%, and Tier 3 - 20%
• By Designation: Directors - 50%, Managers - 30%, and Others - 20%
• By Region: North America - 40%, Europe - 35%, Asia Pacific - 20%, Rest of World - 5%

The key players profiled in the report include Corbion (Netherlands), Evonik Industries AG (Germany), Foster Corporation (US), KLS Martin Group (Germany), DSM Biomedical (US), Ashland Global Holdings Inc. (US), Zeus Company LLC (US), Seqens (France), Reva Medical, LLC (US), and Poly-Med Incorporated (US).

Research Coverage

This report segments the market for bioresorbable polymers based on type, application, and region and provides estimations of value (USD Million) for the overall market size across various regions. A detailed analysis of key industry players has been conducted to provide insights into their business overviews, services, and key strategies, associated with the market for bioresorbable polymers.

Reasons to Buy this Report

This research report is focused on various levels of analysis - industry analysis (industry trends), market share analysis of top players, and company profiles, which together provide an overall view of the competitive landscape, emerging and high-growth segments of the bioresorbable polymers market; high-growth regions; and market drivers, restraints, and opportunities.

The report provides insights on the following pointers:

• Market Penetration: Comprehensive information on bioresorbable polymers offered by top players in the global market
• Analysis of key drivers: (Increasing number of surgical interventions, Boost in demand of biocompatible medical devices, Growing demand in drug delivery application, Favorable reimbursement scenario), opportunities (Electrospinning and 3D Printing Technologies), and challenges (Stringent regulatory framework for medical devices)
• Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product & service launches in the bioresorbable polymers market
• Market Development: Comprehensive information about lucrative emerging markets - the report analyzes the markets for bioresorbable polymers across regions.
• Market Diversification: Exhaustive information about new products, untapped regions, and recent developments in the global bioresorbable polymers market
• Competitive Assessment: In-depth assessment of market shares, strategies, products, and manufacturing capabilities of leading players in the bioresorbable polymers market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKETS COVERED
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 DEFINITION AND INCLUSIONS, BY TYPE
  • 1.3.4 DEFINITION AND INCLUSIONS, BY APPLICATION
  • 1.3.5 YEARS CONSIDERED
  • 1.3.6 CURRENCY CONSIDERED
  • 1.3.7 UNITS CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Interviews with experts - demand and supply sides
    • 2.1.2.2 Key data from primary sources
    • 2.1.2.3 Key industry insights
    • 2.1.2.4 Breakdown of interviews with experts
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 TOP-DOWN APPROACH
  • 2.2.2 BOTTOM-UP APPROACH
• 2.3 GROWTH FORECAST
  • 2.3.1 SUPPLY-SIDE FORECAST
  • 2.3.2 DEMAND-SIDE FORECAST
• 2.4 FACTOR ANALYSIS
• 2.5 DATA TRIANGULATION
• 2.6 RESEARCH ASSUMPTIONS
• 2.7 RESEARCH LIMITATIONS
• 2.8 RISK ASSESSMENT

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 SIGNIFICANT OPPORTUNITIES FOR PLAYERS IN BIORESORBABLE POLYMERS MARKET
• 4.2 BIORESORBABLE POLYMERS MARKET, BY REGION
• 4.3 NORTH AMERICA: BIORESORBABLE POLYMERS MARKET, BY TYPE AND COUNTRY
• 4.4 BIORESORBABLE POLYMERS MARKET, BY APPLICATION AND REGION
• 4.5 BIORESORBABLE POLYMERS MARKET ATTRACTIVENESS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing number of surgical interventions
    • 5.2.1.2 Rising demand for biocompatible medical devices
    • 5.2.1.3 Growing demand for drug delivery applications
    • 5.2.1.4 Favorable reimbursement scenario
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Increasing preference for minimally invasive surgeries
    • 5.2.2.2 Higher cost of bioresorbable polymers than conventional polymers
    • 5.2.2.3 Lack of quality control measures in emerging countries
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Electrospinning and 3D printing technologies
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Stringent regulatory framework for medical devices
    • 5.2.4.2 Requirement of skilled personnel for effective use of bioresorbable medical products
• 5.3 PORTER'S FIVE FORCES ANALYSIS
  • 5.3.1 THREAT OF NEW ENTRANTS
  • 5.3.2 THREAT OF SUBSTITUTES
  • 5.3.3 BARGAINING POWER OF SUPPLIERS
  • 5.3.4 BARGAINING POWER OF BUYERS
  • 5.3.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.4 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.4.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.4.2 BUYING CRITERIA
• 5.5 MACROECONOMIC INDICATORS
  • 5.5.1 GDP TRENDS AND FORECAST OF MOST PROMINENT ECONOMIES

6 INDUSTRY TRENDS

• 6.1 SUPPLY CHAIN ANALYSIS
  • 6.1.1 RAW MATERIAL SUPPLIERS
  • 6.1.2 MANUFACTURERS
  • 6.1.3 DISTRIBUTORS
  • 6.1.4 END-USE INDUSTRIES
• 6.2 PRICING ANALYSIS
  • 6.2.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY APPLICATION
  • 6.2.2 AVERAGE SELLING PRICE TREND, BY REGION
• 6.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 6.4 ECOSYSTEM ANALYSIS
• 6.5 TECHNOLOGY ANALYSIS
  • 6.5.1 KEY TECHNOLOGIES
    • 6.5.1.1 Electrospinning technology in bioresorbable polymers
  • 6.5.2 COMPLEMENTARY TECHNOLOGIES
    • 6.5.2.1 Melt extrusion technology
• 6.6 CASE STUDY ANALYSIS
  • 6.6.1 BIORESORBABLE POLYMER SCAFFOLDS FOR TISSUE ENGINEERING
  • 6.6.2 BIORESORBABLE MATERIALS FOR CARDIOVASCULAR DEVICES
  • 6.6.3 BIORESORBABLE 3D-PRINTED PATIENT-SPECIFIC IMPLANTS FOR CRANIO-MAXILLOFACIAL SURGERY
• 6.7 TRADE ANALYSIS
  • 6.7.1 IMPORT SCENARIO (HS CODE 390770)
  • 6.7.2 EXPORT SCENARIO (HS CODE 390770)
• 6.8 REGULATORY LANDSCAPE
  • 6.8.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 6.8.2 REGULATORY FRAMEWORK
    • 6.8.2.1 Regulations impacting bioresorbable polymers business
    • 6.8.2.2 FDA guidelines for bioabsorbable polymers in medical devices
    • 6.8.2.3 REACH (Registration, evaluation, authorization and restriction of chemicals)
    • 6.8.2.4 ISO 10993 (Biological evaluation of medical devices)
    • 6.8.2.5 EU medical device regulation (MDR) for bioresorbable polymers
    • 6.8.2.6 ASTM standards for absorbable polymers and implants
• 6.9 KEY CONFERENCES AND EVENTS, 2024-2025
• 6.10 INVESTMENT AND FUNDING SCENARIO
• 6.11 PATENT ANALYSIS
  • 6.11.1 APPROACH
  • 6.11.2 PATENT TYPES
  • 6.11.3 TOP APPLICANTS
  • 6.11.4 JURISDICTION ANALYSIS
• 6.12 IMPACT OF AI/GEN AI ON BIORESORBABLE POLYMERS MARKET

7 BIORESORBABLE POLYMERS MARKET, BY TYPE

• 7.1 INTRODUCTION
• 7.2 POLYLACTIC ACID (PLA)
  • 7.2.1 RISING DEMAND FOR ORTHOPEDIC DEVICES TO DRIVE MARKET
• 7.3 POLYGLYCOLIC ACID (PGA)
  • 7.3.1 USE IN SUTURES AND OTHER MEDICAL IMPLANTS TO PROPEL MARKET
• 7.4 POLY (LACTIC-CO-GLYCOLIC ACID) (PLGA)
  • 7.4.1 BIOCOMPATIBILITY AND BIODEGRADABILITY TO DRIVE MARKET
• 7.5 POLYCAPROLACTONE (PCL)
  • 7.5.1 DRUG DELIVERY, TISSUE ENGINEERING, AND ORTHOPEDIC DEVICE APPLICATIONS TO DRIVE MARKET
• 7.6 OTHER TYPES

8 BIORESORBABLE POLYMERS MARKET, BY APPLICATION

• 8.1 INTRODUCTION
• 8.2 ORTHOPEDIC DEVICES
  • 8.2.1 HIGH CONSUMPTION IN NORTH AMERICA AND EUROPE TO DRIVE MARKET
• 8.3 DRUG DELIVERY
  • 8.3.1 SIGNIFICANT DEMAND FOR ORAL CAPSULES TO DRIVE MARKET
• 8.4 OTHER APPLICATIONS

9 BIORESORBABLE POLYMERS MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 US
    • 9.2.1.1 Growing demand for orthopedic devices and drug delivery applications to drive market
  • 9.2.2 CANADA
    • 9.2.2.1 Increasing geriatric population to boost demand
  • 9.2.3 MEXICO
    • 9.2.3.1 Rising medical tourism to propel market growth
• 9.3 ASIA PACIFIC
  • 9.3.1 CHINA
    • 9.3.1.1 Economic growth to be major driver for market growth
  • 9.3.2 JAPAN
    • 9.3.2.1 Rapidly aging population to drive market
  • 9.3.3 INDIA
    • 9.3.3.1 Growing pharmaceutical and medical industries to drive market
  • 9.3.4 SOUTH KOREA
    • 9.3.4.1 Increasing access to healthcare facilities to drive market
• 9.4 EUROPE
  • 9.4.1 GERMANY
    • 9.4.1.1 Established healthcare industry and technological advancements offer opportunities for market growth
  • 9.4.2 UK
    • 9.4.2.1 Increasing healthcare expenditure to drive market growth
  • 9.4.3 ITALY
    • 9.4.3.1 Orthopedic and pharmaceutical applications to propel market
  • 9.4.4 FRANCE
    • 9.4.4.1 Initiatives to boost healthcare sector to drive demand
  • 9.4.5 RUSSIA
    • 9.4.5.1 Orthopedics, healthcare, and pharmaceutical segments contribute significantly to market growth
• 9.5 MIDDLE EAST & AFRICA
  • 9.5.1 MIDDLE EAST
    • 9.5.1.1 Improving healthcare infrastructure to drive market
  • 9.5.2 AFRICA
    • 9.5.2.1 South Africa to be largest market
• 9.6 SOUTH AMERICA
  • 9.6.1 BRAZIL
    • 9.6.1.1 Rising demand for implants in surgeries to drive market
  • 9.6.2 ARGENTINA
    • 9.6.2.1 Investments by major players to drive market

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 10.3 MARKET SHARE ANALYSIS
• 10.4 REVENUE ANALYSIS
• 10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023
  • 10.5.1 STARS
  • 10.5.2 EMERGING LEADERS
  • 10.5.3 PERVASIVE PLAYERS
  • 10.5.4 PARTICIPANTS
  • 10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023
    • 10.5.5.1 Company footprint
    • 10.5.5.2 Type footprint
    • 10.5.5.3 Application footprint
    • 10.5.5.4 Region footprint
• 10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023
  • 10.6.1 PROGRESSIVE COMPANIES
  • 10.6.2 RESPONSIVE COMPANIES
  • 10.6.3 DYNAMIC COMPANIES
  • 10.6.4 STARTING BLOCKS
  • 10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023
    • 10.6.5.1 Detailed list of key startups/SMEs
    • 10.6.5.2 Competitive benchmarking of key startups/SMEs
• 10.7 BRAND/PRODUCT COMPARISON
• 10.8 COMPANY VALUATION AND FINANCIAL METRICS
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 PRODUCT LAUNCHES
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 CORBION
    • 11.1.1.1 Business overview
    • 11.1.1.2 Products/Solutions/Services offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Right to win
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses and competitive threats
  • 11.1.2 EVONIK INDUSTRIES AG
    • 11.1.2.1 Business overview
    • 11.1.2.2 Products/Solutions/Services offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Expansions
      • 11.1.2.3.2 Deals
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Right to win
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses and competitive threats
  • 11.1.3 FOSTER CORPORATION
    • 11.1.3.1 Business overview
    • 11.1.3.2 Products/Solutions/Services offered
    • 11.1.3.3 MnM view
      • 11.1.3.3.1 Right to win
      • 11.1.3.3.2 Strategic choices
      • 11.1.3.3.3 Weaknesses and competitive threats
  • 11.1.4 KLS MARTIN GROUP
    • 11.1.4.1 Business overview
    • 11.1.4.2 Products/Solutions/Services offered
    • 11.1.4.3 MnM view
      • 11.1.4.3.1 Right to win
      • 11.1.4.3.2 Strategic choices
      • 11.1.4.3.3 Weaknesses and competitive threats
  • 11.1.5 DSM BIOMEDICAL
    • 11.1.5.1 Business overview
    • 11.1.5.2 Products/Solutions/Services offered
    • 11.1.5.3 MnM view
      • 11.1.5.3.1 Right to win
      • 11.1.5.3.2 Strategic choices
      • 11.1.5.3.3 Weaknesses and competitive threats
  • 11.1.6 ASHLAND GLOBAL HOLDINGS INC.
    • 11.1.6.1 Business overview
    • 11.1.6.2 Products/Solutions/Services offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Product launches
      • 11.1.6.3.2 Expansions
  • 11.1.7 ZEUS COMPANY LLC
    • 11.1.7.1 Business overview
    • 11.1.7.2 Products/Solutions/Services offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Product launches
  • 11.1.8 SEQENS
    • 11.1.8.1 Business overview
    • 11.1.8.2 Products/Solutions/Services offered
  • 11.1.9 REVA MEDICAL, LLC
    • 11.1.9.1 Business overview
    • 11.1.9.2 Products/Solutions/Services offered
  • 11.1.10 POLY-MED INCORPORATED
    • 11.1.10.1 Business overview
    • 11.1.10.2 Products/Solutions/Services offered
• 11.2 OTHER PLAYERS
  • 11.2.1 BEZWADA BIOMEDICAL, LLC
  • 11.2.2 NOMISMA HEALTHCARE PVT. LTD.
  • 11.2.3 BMG INC.
  • 11.2.4 POLYSCIENCES, INC.
  • 11.2.5 HUIZHOU FORYOU MEDICAL DEVICES CO., LTD.
  • 11.2.6 MUSASHINO CHEMICAL LABORATORY, LTD.
  • 11.2.7 HENAN XINGHAN BIOLOGICAL TECHNOLOGY CO., LTD.

12 ADJACENT AND RELATED MARKETS

• 12.1 INTRODUCTION
• 12.2 LIMITATIONS
• 12.3 POLY LACTIC ACID MARKET
  • 12.3.1 MARKET DEFINITION
  • 12.3.2 MARKET OVERVIEW
• 12.4 POLY LACTIC ACID MARKET, BY REGION
  • 12.4.1 EUROPE
  • 12.4.2 NORTH AMERICA
  • 12.4.3 ASIA PACIFIC
  • 12.4.4 SOUTH AMERICA
  • 12.4.5 MIDDLE EAST & AFRICA

13 APPENDIX

• 13.1 DISCUSSION GUIDE
• 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 13.3 CUSTOMIZATION OPTIONS
• 13.4 RELATED REPORTS
• 13.5 AUTHOR DETAILS